FDA Grants Early Access for Revolution Medicines' Pancreatic Cancer Oral Therapy
The U.S. Food and Drug Administration has authorized early access for Revolution Medicines' oral KRAS inhibitor daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The drug, which the company said doubled survival versus chemotherapy in a late-stage trial, is also under evaluation in late-stage non-small ce…